BioSpace News Archive

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that, as disclosed in the Company’s Definitive Proxy Statement for the Company’s 2020 Annual Meeting of Stockholders, due to the public health impact of the COVID-19 pandemic, the Company’s Annual Meeting of Stockholders

-- Completed Strategic Asset Sales of NUCYNTA ® Franchise and Gralise ® Totaling $502.5 Million -- -- Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible Debt -- -- Merger with Zyla Life Sciences On Track and Expected to Close Shortly After the Company’s 2020 Annual Meeting on May 19, 2020 -- LAKE FOREST, Ill., May 11, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today reported financial results for the qu

CNS Pharmaceuticals, Inc. announced that since the May 1st, 2020 temporary suspension by the Securities and Exchange Commission in the trading of CNS Pharmaceuticals, Inc. securities, additional information has come to the Company’s attention regarding information disseminated by third parties.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it is expanding capacity for viral vector development and manufacturing services with construction of a new commercia

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , today announced the appointment of Joseph Truitt as Chief Executive Officer. Mr. Truitt was appoint

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics with a rich history of bringing critical tests for infectious diseases to market, today announced it is working with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, to expand COVID-19 antibody testing to more than 20 Quest

- Reached Agreement to be Acquired by Alexion; Transaction Expected to Close in Third Quarter - - Andexxa®/Ondexxya® Global Net Product Revenues of $25.6 Million - [11-May-2020] SOUTH SAN FRANCISCO, Calif. , May 11, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today reported financial results for the three months ended March

- 19% year-over-year increase in royalty revenues for XIAFLEX® - Highly experienced biopharma executive, Joseph Truitt, named as Chief Executive Officer and Mike Sherman and Corey Fishman appointed to Board of Directors - Initiation of CCH studies for plantar fibromatosis and adhesive capsulitis in 2H20 [11-May-2020] WILIMINGTON, Del., May 11, 2020

The CorVent™ Single-Use Ventilator is poised to help address critical unmet needs highlighted during the COVID-19 pandemic

Reported positive top-line data from AXA1125-003, with clinically relevant reductions in liver fat content, insulin resistance and fibroinflammation observed in subjects with NAFLD receiving AXA1125 Completed enrollment of AXA1665-002, with data readout expected in Q3 2020 Announced AXA2678 patent issuance and oral presentation at ICSFR Launched new corporate website at www.axcellahealth.com CAMBRIDGE, Mass.--( BUSINE